라이센싱을위한, Cortellis 최적의활용법

Cortellis Deal Intelligence

이경미

2019. 6. 27

1

Agenda

Cortellis 소개

라이센싱을위한 CCI 활용법?

Live Demo

Summary

2.

3.

4.

5.

라이센싱트렌드1.

Agenda

Cortellis 소개

라이센싱을위한 CCI 활용법?

Live Demo

Summary

2.

3.

4.

5.

라이센싱트렌드1.

4** Funding $6.0 (2017), $14.9 (2018); Commercial $24.0, $2.0; Service <$0.1, $0.2; Other (royalty buy-out, spin-out, settlement) $4.4, $1.2.

2018 Vs 2017: 글로벌거래트렌드

M&A, 482 M&A, 449

Licenses, 1811

Licenses, 1658

Asset Purch, 210 Asset Purch,

184

Funding, 941

Funding, 734

Commercial, 563

Commercial, 560

Service, 465

Service, 376

Other, 50

Other, 53

0

500

1000

1500

2000

2500

3000

3500

4000

4500

5000

2017 2018

Volume

4014

4522

M&A, $256M&A, $276

Licenses, $88

Licenses, $111

Asset Purch, $33

Asset Purch, $22

$0

$50

$100

$150

$200

$250

$300

$350

$400

$450

2017 2018

Announced $ billion

$428 B

$392 B

**

**

Source: Cortellis Deal Intelligence 2019

US FDA 승인약물: 거래를통한혁신추진

5Insert footer

All NME approvals Oncology NME approvals

US FDA CDER NME approvals resulting from licensing/acquisition (2010-2018)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

2010 2011 2012 2013 2014 2015 2016 2017 2018*

Source: FDA, Clarivate Analytics analysis

6

• Covers key transactions types, M&As, Licenses/joint ventures, Research-only deals, and Other (Asset Purchases, Equity Stakes, Spin-outs), with identifiable therapeutic focus areas.• Covers all technologies.

• Not shown: Other, Genitourinary, Musculoskeletal, Toxicity, Unknown and Not Applicable therapy area deals. • Companies are the top 30 pharmas as ranked by 2017 revenues.

글로벌제약사: 거래를통한질환포트폴리오확장또는강화

Number of buy-side transactions by therapy area for top pharma dealmakers

J&J

Me

rck

No

vart

is A

G

Ro

che

Eli L

illy

& C

o

Take

da

San

ofi

AZ

No

vo N

ord

isk

Pfi

zer

BI

Ab

bV

ie

Gil

ead

Ast

ell

as

Bio

gen

Me

rck

KG

aA

Ce

lge

ne

Dai

ich

i San

kyo

GSK

Am

gen

Bay

er

BM

S

Myl

an

Ots

uka

All

erg

an

CSL

Shir

e

UC

B

Teva

TOTA

L

Oncology 9 17 8 12 2 3 3 9 6 4 5 5 3 7 1 6 1 2 1 1 3 108

Neuroscience 6 1 3 3 3 3 1 1 1 2 1 7 3 2 1 2 40

Immuno/Inflam 2 1 4 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 23

Endo/Met 2 3 1 8 1 1 16

Infection 1 1 1 2 5 1 1 2 1 1 16

Diversified 1 3 1 2 3 1 1 1 13

GI 2 1 4 1 1 9

Dermatology 3 1 1 5

Hematology 1 2 1 1 5

Ophthalm 3 1 1 5

Respiratory 1 1 1 1 1 5

Cardiology 1 2 1 4

Total 27 20 20 18 14 14 13 12 12 12 9 8 8 7 7 7 6 6 6 3 3 3 3 3 2 2 2 2 0 222

Source: Cortellis Deal Intelligence 2019

Agenda

Cortellis 소개

라이센싱을위한 CCI 활용법?

Live Demo

Summary

2.

3.

4.

5.

라이센싱트렌드1.

: DATABASE

THE COMPLETE SOLUTION FOR DRUG LIFECYCLE

8

Research

Market Landscape

Clinical

Regulatory

Post-Launch

CORTELLIS CLINICAL

TRIALS INTELLIGENCE

CORTELLIS

REGULATORY

INTELLIGENCE

CORTELLIS

COMPETITIVE

INTELLIGENCE

CORTELLIS

DEAL

INTELLIGENCE

IPD

BIOWORLDNEWPORT THOMSON

INNOVATION

METACORE INTEGRITY/

DRA

WOS

Competitive Intelligence Clinical Trials Intelligence Regulatory Intelligence Deal Intelligence

• 의약품 (시판&개발파이프라인), 회사, 임상, 거래, 특허, 논문, 학회자료등주요 10가지내용

• 질환별, 기전별, 기술별, 회사별시장분석도구

• Clinicaltrials.gov이외의각국인허가/임상기관으로부터정보수집

• 임상시험결과값/부작용값함께제공

• 임상시험기간, 환자수, 지역등에따른 Spot Fire 분석

• 80여개의국가의개별인허가규정비교분석

• Marketing authorization, Pricing & Reimburse, Quality assurance 등약물개발규정포함

• Advanced therapy, Medical device, Bio-similar/generics, Pediatric use, Orphan drugs 등특정규정포함

• 더넓은커버리지 (88,000 deals and 29,000 contracts for CDI)

• Deal term breakdown (upfront, Dev/Reg milestone, Equity)

• M&A거래

• 원본계약서제공, 질환별분석

• Financial summary 제공

9

CORTELLIS : Body of Knowledge

Agenda

Cortellis 소개

라이센싱을위한 CCI 활용법?

Live Demo

Summary

2.

3.

4.

5.

라이센싱트렌드1.

• 공개된거래규모를보기위해, 라이센싱거래검색

• 평균 (Average), 중간값 (Median) 거래규모의확인필요

11

“DEAL VALUE”에집중!

최적의라이센싱을위한 Cortellis의활용법?

12Insert footer

Outlier 확인, 분석에서제외또는포함

최적의라이센싱을위한 Cortellis의활용법?

13Insert footer

지역, 질환, 제품과옵션수와같은주요필드검토.

최적의라이센싱을위한 Cortellis 활용법?

Agenda

Cortellis 소개

라이센싱을위한 CCI 활용법?

Live Demo

Summary

2.

3.

4.

5.

라이센싱트렌드1.

• 거래규모에집중!

✓ 라이센싱검색

: 평균/ 중간값확인

Outlier 제외

지역, 질환및제품/옵션수와같은주요필드확인

• 글로벌제약사의거래트렌드분석

• In Cortellis Deal Intelligence,

✓ 거래규모차트로확인및활용

✓ 분석결과에서 Outlier 확인및제외

✓ 주요필드검토

15Insert footer

Summary

감사합니다.

16

© 2019 Clarivate Analytics. All rights reserved. Republication or redistribution of Clarivate Analytics content, including by framing or similar means, is prohibited without the prior written consent of Clarivate Analytics. Cortellis and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.